Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05506943 · ClinicalTrials.gov registry record · Phase 2
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
A Phase 2 study of Cholangiocarcinoma and Biliary Tract Cancer, sponsored by Compass Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT05506943: Active Phase 2 study of Cholangiocarcinoma and Biliary Tract Cancer, sponsored by Compass Therapeutics.
NCT05506943 is a Phase 2 study of Cholangiocarcinoma and Biliary Tract Cancer that is active but no longer recruiting, run by Compass Therapeutics. The registered enrollment target is 150 participants, below the 383-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05506943, a Phase 2 study of Cholangiocarcinoma and Biliary Tract Cancer, is active but no longer recruiting, sponsored by Compass Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
Primary Outcome
Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR) as assessed by RECIST 1.1
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG CTX-009
Study Locations (20)
California
- University of Southern California Norris Comprehensive Cancer Center - Los Angeles
- Stanford Medicine Cancer Center - Palo Alto
- University of California San Francisco - San Francisco
Florida
- University of Florida - Gainesville
- Mayo Clinic Jacksonville - Jacksonville
- AdventHealth Orlando - Orlando
Arizona
- Mayo Clinic Arizona - Phoenix
- University of Arizona - Tucson
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
New Mexico
- The University of New Mexico - Albuquerque
- Memorial Medical Center - Las Cruces
Colorado
- Rocky Mountain Cancer Centers, LLP - Aurora
Louisiana
- Ochsner Clinic Foundation - New Orleans
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What the registry record for NCT05506943 still lists
NCT05506943 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 383-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (61% lower).
The record links to 4 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT05506943 names 20 study sites across 13 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05506943 about?
NCT05506943 is a clinical study titled "A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)". This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
What is the current status of trial NCT05506943?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2023-01-09. Estimated completion is 2025-12.
What conditions does trial NCT05506943 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Biliary Tract Cancer, Gallbladder Cancer, Ampullary Cancer.
What interventions are being tested in trial NCT05506943?
The interventions under investigation include: Paclitaxel (DRUG), CTX-009 (DRUG).
Who is sponsoring clinical trial NCT05506943?
This trial is sponsored by Compass Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05506943 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05506943's enrollment target sits among peer trials
150 25th of 60 higher than 36 of 60 other Cholangiocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cholangiocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RECRUITING · Phase 2
-
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
RECRUITING · Phase 2
-
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
RECRUITING · Phase 2
-
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI